Clevudine myopathy in patients with chronic hepatitis B.
Clevudine (L-FMAU) is a thymidine l-nucleoside analogue that was recently introduced for the treatment of chronic hepatitis B virus infection. Previous studies showed that clevudine has potent and sustained antiviral activity without causing viral resistance. No severe adverse event occurred during clinical trials. We describe two cases of drug-induced myopathy during long-term treatment of chronic hepatitis B with clevudine.
Kim
Byung Kook
BK
Department of Internal Medicine, Konkuk University School of Medicine, 4-12 Hwayang-dong, Gwangjin-gu, Seoul 143-729, Republic of Korea.
Oh
Jeeyoung
J
Kwon
So Young
SY
Choe
Won Hyeok
WH
Ko
Soon Young
SY
Rhee
Kyoung Hoon
KH
Seo
Tae Ho
TH
Lim
So Dug
SD
Lee
Chang Hong
CH
D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects*; D001086:Arabinofuranosyluracil / Q000009:adverse effects / Q000031:analogs & derivatives*; D003402:Creatine Kinase / Q000097:blood; D004279:DNA, Viral / Q000097:blood; D004576:Electromyography; D005260:Female; D006515:Hepatitis B virus / Q000302:isolation & purification; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D008875:Middle Aged; D009135:Muscular Diseases / Q000139:chemically induced* / Q000473:pathology / Q000503:physiopathology
D000998:Antiviral Agents; D004279:DNA, Viral; D001086:Arabinofuranosyluracil; D003402:Creatine Kinase; C034935:clevudine